Literature DB >> 16012415

Opioid therapy for chronic noncancer pain: practice guidelines for initiation and maintenance of therapy.

F Coluzzi1, M Pappagallo.   

Abstract

Contemporary standard pharmacological care for the treatment of noncancer pain includes the use of opioid medications. The responsiveness of neuropathic pain to opioids has long been an area of controversy. Evidence from multiple randomized controlled trials indicates that opioids can relieve pain in a variety of neuropathic pain syndromes. Opioids are typically reserved for moderate to severe pain that cannot be relieved by the nonsteroidal anti-inflammatory drugs (NSAIDs). Opioids are often used in combination with other adjuvants or other analgesic agents. The advantage of opioids is the lack of a ceiling effect of the pure mu opioid agonists. The disadvantages of these drugs are a series of mechanism-based opioids-related side effects (e.g., nausea, drowsiness, constipation) and the potential issue of their abuse and misuse. Each patient needs to undergo a comprehensive evaluation and receive education on the treatment. The physician must be well conversant with the differential diagnosis and definitions of physical dependence, tolerance, pseudotolerance, aberrant behaviors, addiction, and pseudoaddiction. No specific opioid drug is intrinsically ''better'' than the others. Opioid rotation refers to the switch from one opioid to another when the degree of analgesia obtained is limited by the persistence of adverse effects or the occurrence of clinically relevant tolerance. This approach is based on the observation that a patient's response varies from opioid to opioid. At present, after 1) appropriate selection of patients and 2) longitudinal patient care with routine assessment of degree of analgesia, functional daily activities, adverse events and aberrant behaviors is carried out, opioid therapy can be the safest and most effective treatment measure for quality of life improvement in the chronic pain patient.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16012415

Source DB:  PubMed          Journal:  Minerva Anestesiol        ISSN: 0375-9393            Impact factor:   3.051


  23 in total

1.  Oxymorphone Extended-Release Tablets (Opana ER) For the Management of Chronic Pain: A Practical Review for Pharmacists.

Authors:  David S Craig
Journal:  P T       Date:  2010-06

Review 2.  Oxycodone/Naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipation.

Authors:  Celeste B Burness; Gillian M Keating
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

3.  Transdermal buprenorphine in non-oncological moderate-to-severe chronic pain.

Authors:  Antonio Gatti; Mario Dauri; Francesca Leonardis; Giuseppe Longo; Franco Marinangeli; Massimo Mammucari; Alessandro Fabrizio Sabato
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

4.  Moving beyond misuse and diversion: the urgent need to consider the role of iatrogenic addiction in the current opioid epidemic.

Authors:  Gillian A Beauchamp; Erin L Winstanley; Shawn A Ryan; Michael S Lyons
Journal:  Am J Public Health       Date:  2014-09-11       Impact factor: 9.308

5.  sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain.

Authors:  Dan Kaufmann; Peter J West; Misty D Smith; Boris Yagen; Meir Bialer; Marshall Devor; H Steve White; K C Brennan
Journal:  Pharmacol Res       Date:  2016-11-24       Impact factor: 7.658

6.  Contribution of DNMT1 to Neuropathic Pain Genesis Partially through Epigenetically Repressing Kcna2 in Primary Afferent Neurons.

Authors:  Linlin Sun; Xiyao Gu; Zhiqiang Pan; Xinying Guo; Jianbin Liu; Fidelis E Atianjoh; Shaogen Wu; Kai Mo; Bo Xu; Lingli Liang; Alex Bekker; Yuan-Xiang Tao
Journal:  J Neurosci       Date:  2019-06-10       Impact factor: 6.167

7.  Feasibility study of rapid opioid rotation and titration.

Authors:  Marina Korkmazsky; Javid Ghandehari; Angela Sanchez; Hung-Mo Lin; Huong-Mo Lin; Marco Pappagallo
Journal:  Pain Physician       Date:  2011 Jan-Feb       Impact factor: 4.965

8.  Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials.

Authors:  Oliver Löwenstein; Petra Leyendecker; Eberhard A Lux; Mark Blagden; Karen H Simpson; Michael Hopp; Björn Bosse; Karen Reimer
Journal:  BMC Clin Pharmacol       Date:  2010-09-29

9.  Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain.

Authors:  A Sandner-Kiesling; P Leyendecker; M Hopp; L Tarau; J Lejcko; W Meissner; P Sevcik; M Hakl; R Hrib; R Uhl; H Dürr; K Reimer
Journal:  Int J Clin Pract       Date:  2010-03-29       Impact factor: 2.503

Review 10.  Practical guide to the management of acute and chronic pain in the presence of drug tolerance for the healthcare practitioner.

Authors:  Nalini Vadivelu; Harman Singh-Gill; Gopal Kodumudi; Aaron Joshua Kaye; Richard D Urman; Alan David Kaye
Journal:  Ochsner J       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.